N/A Completed N=30 Randomized Treatment

Improving Vitamin D Status In Cystic Fibrosis

Cystic fibrosis

Source: ClinicalTrials.gov NCT00450073 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2014

Primary outcomePrimary: 25-hydroxyvitamin D — 21.2; 24.4; 28.2 ng/mL

Summary

The purpose of this study is to establish an effective method to correct vitamin D deficiency in subjects with cystic fibrosis. The investigators will examine cholecalciferol, ergocalciferol and UV light.

Outcome Measures

Outcome	Result	p-value
PRIMARY 25-hydroxyvitamin D	21.2; 24.4; 28.2	—
SECONDARY Parathyroid Hormone, Serum C-telopeptide, Osteocalcin	—	—

Eligibility Criteria

Inclusion Criteria

Subjects seen initially at the Emory CF center between the months of September and December
Age > 16, both males and females, confirmed cystic fibrosis by genetic testing or sweat testing, FEV1 > 40%.

Exclusion Criteria

History of lung transplant or awaiting lung transplantation
Current hospitalization or greater than 6 hospitalizations/year
History of malignancy, renal disease (calculated GFR 3 times upper limit of normal), greater than 10 mg of prednisone or equivalent, hypercalcemia
History of easily burned skin after sunlight exposure, taking medications with may cause photosensitivity
History of skin cancer or multiple moles or family history of skin cancer
Moderate to severe vitamin D deficiency (25(OH)D ≤ 15 ng/ml).

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00450073). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.